News Go

News & articles

Sunovion Pharma to buy Canada's Cynapsus for $624 million

(Reuters) – Sunovion Pharmaceuticals Inc, a unit of Japan’s Dainippon Sumitomo Pharma Co Ltd <4506.T>, said it would buy Canada’s Cynapsus Therapeutics Inc for about $624 million.

The price of the Canadian drugmaker’s U.S.-listed shares hit $40 in extended trading on Wednesday, more than double the closing price of $18.36. The announced purchase price of $40.50 per share in cash was a 120.5 percent premium over that closing price.

Through the deal, Sunovion will acquire Cynapsus’ drug candidate, APL-130277, which is currently in its phase three clinical trial stage. It is designed to be an easy to administer, sublingual thin film of apomorphine to manage OFF episodes associated with Parkinson’s disease(PD).

People with Parkinson’s disease suffer from motor fluctuations which oscillate between “off” times, a state of decreased mobility, and “on” times, or periods when the medication…

Read the full article from the author…

Back to Top